title: Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.
abstract: Brentuximab vedotin is a promising antibody-drug conjugate (ADC) targeting CD30 of tumor cells. It selectively delivers monomethyl auristatin E (MMAE) into CD30-expressing cells and induces tumor cell apoptosis. Various clinical trials have provided evidence that it is effective in relapsed or refractory Hodgkin's lymphoma (HL), and it has also shown its advantages in other CD30-positive lymphomas. In this review, we focus on the structure, mechanisms, and pharmacokinetics of brentuximab vedotin. We also summarize clinical trials with brentuximab vedotin and make recommendations for brentuximab vedotin in the treatment of relapsed or refractory HL.
authors.affiliation: Department of Hematology and Oncology (Key Department of Jiangsu Medicine), Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu Province, People's Republic of China.
authors.forename: Runzhe
authors.initials: R
authors.lastname: Chen
authors.affiliation: Department of Hematology and Oncology (Key Department of Jiangsu Medicine), Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu Province, People's Republic of China.
authors.forename: Baoan
authors.initials: B
authors.lastname: Chen
mesh_terms: D000079963:Brentuximab Vedotin; D002986:Clinical Trials as Topic; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012008:Recurrence
chemical_list: D018796:Immunoconjugates; D000079963:Brentuximab Vedotin
keywords: CD30-positive; antitumor effects; clinical trials; lymphoma; monoclonal antibody; tumor cells
references.citation: Pharmacotherapy. 2013 Jan;33(1):93-104
references.pmid: 23307550
references.citation: Expert Opin Investig Drugs. 2012 Feb;21(2):205-16
references.pmid: 22127011
references.citation: Expert Opin Biol Ther. 2014 Oct;14(10):1519-26
references.pmid: 25200691
references.citation: J Adv Pract Oncol. 2012 May;3(3):184-90
references.pmid: 25031945
references.citation: Blood Rev. 2015 Mar;29(2):93-100
references.pmid: 25445718
references.citation: Blood. 2012 Aug 16;120(7):1470-2
references.pmid: 22786877
references.citation: J Natl Compr Canc Netw. 2013 Aug;11(8):968-76
references.pmid: 23946175
references.citation: Cancer Sci. 2014 Jul;105(7):840-6
references.pmid: 24814862
references.citation: Leuk Lymphoma. 2014 Oct;55(10):2328-34
references.pmid: 24359243
references.citation: Am Soc Clin Oncol Educ Book. 2012;:162-6
references.pmid: 24451728
references.citation: Mediterr J Hematol Infect Dis. 2014 Jul 01;6(1):e2014050
references.pmid: 25045458
references.citation: Onco Targets Ther. 2014 Sep 26;7:1717-22
references.pmid: 25328405
references.citation: Expert Rev Hematol. 2013 Aug;6(4):361-73
references.pmid: 23991923
references.citation: Hematology Am Soc Hematol Educ Program. 2009;:507-19
references.pmid: 20008236
references.citation: Blood. 2013 Apr 4;121(14):2715-24
references.pmid: 23343832
references.citation: Oncologist. 2012;17(8):1073-80
references.pmid: 22855426
references.citation: Bone Marrow Transplant. 2014 May;49(5):599-606
references.pmid: 24442246
references.citation: J Clin Oncol. 2012 Jun 20;30(18):2183-9
references.pmid: 22454421
references.citation: Expert Opin Pharmacother. 2014 Jun;15(8):1139-51
references.pmid: 24749840
references.citation: Blood. 2012 Jul 19;120(3):560-8
references.pmid: 22510871
references.citation: Curr Med Res Opin. 2015 Mar;31(3):537-45
references.pmid: 25598441
references.citation: Blood. 2014 Nov 20;124(22):3197-200
references.pmid: 25293772
references.citation: Haematologica. 2013 Aug;98(8):1232-6
references.pmid: 23645687
references.citation: Blood. 2013 Aug 15;122(7):1233-42
references.pmid: 23838350
references.citation: Ann Pharmacother. 2012 Mar;46(3):377-83
references.pmid: 22395252
references.citation: Leuk Lymphoma. 2011 Sep;52(9):1641-54
references.pmid: 21619423
references.citation: J Natl Compr Canc Netw. 2014 Apr;12(4):465-71
references.pmid: 24717566
references.citation: Blood. 2014 May 15;123(20):3095-100
references.pmid: 24652992
references.citation: Clin Cancer Res. 2012 Jan 1;18(1):248-55
references.pmid: 22080439
references.citation: Expert Opin Biol Ther. 2012 Oct;12(10):1415-21
references.pmid: 22937794
references.citation: Blood. 2015 Feb 26;125(9):1394-402
references.pmid: 25573987
references.citation: Am J Health Syst Pharm. 2013 Apr 1;70(7):589-97
references.pmid: 23515511
references.citation: N Engl J Med. 2010 Nov 4;363(19):1812-21
references.pmid: 21047225
references.citation: Ther Adv Hematol. 2012 Aug;3(4):209-25
references.pmid: 23606932
references.citation: Hematol Oncol. 2014 Dec;32(4):187-91
references.pmid: 24301099
references.citation: Curr Treat Options Oncol. 2014 Jun;15(2):210-25
references.pmid: 24570331
references.citation: Hematol Oncol Clin North Am. 2014 Feb;28(1):27-32
references.pmid: 24287065
references.citation: J Clin Oncol. 2012 Jun 20;30(18):2190-6
references.pmid: 22614995
references.citation: Clin Cancer Res. 2013 Jan 1;19(1):22-7
references.pmid: 23155186
references.citation: Blood. 2015 Feb 19;125(8):1236-43
references.pmid: 25533035
references.citation: Jpn J Clin Oncol. 2015 Feb;45(2):137-45
references.pmid: 25489004